Ferric carboxymaltose in the management of anemia due to non-obstetric conditions in women: a sub-group analysis of a large multi-center real-world study/PROMISE from India
Keywords:Anemia, Efficacy, Females, Ferric carboxymaltose, India, Iron deficiency, Safety, Women
Background: Real-world data on the efficacy and safety of intravenous ferric carboxymaltose (FCM) for treating iron deficiency anemia (IDA) in Indian women is limited.
Methods: This was a sub-group analysis of the real-world PROMISE study, which analyzed data of women who received FCM for the management of IDA due to non-obstetric causes. Hematological parameters were retrieved from the charts at baseline and at 4±1 week and analyzed for the whole sub-group and by the severity of anemia.
Results: In 442 women with anemia, Hb and serum ferritin improved by 2.77 gm/dl and 62.07 µg/l, respectively (p<0.001 for both) at 4 weeks. There was a significant increase in red blood cell (RBC) count, hematocrit, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) (p<0.001 for all). In 192 subjects with severe anemia, there was a significant increase in Hb by 3.19 gm/dl, serum ferritin by 61.67 µg/l, RBC count, hematocrit, and MCV (p<0.001 for all); and MCH (p=0.002). In 226 subjects with moderate anemia, there was a significant increase in Hb by 2.41 gm/dl, serum ferritin by 62.75 µg/l, and MCV (p<0.001 for all); and MCH (p=0.003). No subject had mild anemia. No new safety signals or serious adverse events were reported. Physicians rated the efficacy and safety of FCM as very good to good in 94.1 and 94.2% of subjects, respectively.
Conclusions: In Indian women, FCM effectively and safely corrects IDA due to non-obstetric causes, in a short span of 4 weeks.
World Health Organization. WHO Global Anaemia estimates, 2021 Edition Global anaemia estimates in women of reproductive age, by pregnancy status, and in children aged 6-59 months. 2021. Available from: https://www.who.int/data/gho/data/themes/topics/anaemia_in_women_and_children. Accessed on 28 July 2022.
Shukla A. NFHS 2019-21: Anemia rising across all age-groups, fertility rate falls below replacement rate for first time. cnbctv18.com. 2021. Available from: https://www.cnbctv18.com/healthcare/national-family-health-survey-points-to-rising-anemia-lower-fertility-rate-11586522.htm. Accessed on 21 December 2021.
World Health Organization. WHO Global Anaemia estimates, 2021 Edition Prevalence of anemia in non-pregnant women (aged 15-49 years). 2021. Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/anaemia-in-non-pregnant-women-prevalence-(-). Accessed on 28 July 2022.
Breymann C, Auerbach M. Iron deficiency in gynecology and obstetrics: clinical implications and management. Hematol Am Soc Hematol Educ Program. 2017;2017(1):152-9.
Kant S. Do we have a magic bullet to treat moderate and severe anemia in pregnant women? Indian J Public Health. 2019;63(3):165.
Seid MH, Butcher AD, Chatwani A. Ferric carboxymaltose as treatment in women with iron-deficiency anemia. Anemia. 2017;2017:9642027.
Ministry of Health and Family Welfare, Government of India. Anemia Mukt Bharat: Intensified National Iron Plus Initiative (I-NIPI): Operational Guidelines for Programme Managers. Ministry of Health and Family Welfare Government of India; 2018. Available from: https://www.fitterfly.com/site/ pdf/anemia-mukt-bharat.pdf. Accessed on 12 January 2022.
Sharma A. Eliminating female anaemia in India: prevalence, challenges and way forward. Social and Political Research Foundation; 2021. Available from: https://sprf.in/wp-content/uploads/2021/04/SPRF-2021_IB_Anaemia-among-Indian-Women_Final.pdf. Accessed on 12 February 2022.
Rai RK, Fawzi WW, Barik A, Chowdhury A. The burden of iron-deficiency anaemia among women in India: how have iron and folic acid interventions fared? WHO South-East Asia J Public Health. 2018;7(1):18.
Sharma S, Sharma P, Tyler LN. Transfusion of blood and blood products: indications and complications. Am Fam Phys. 2011;83(6):719-24.
Cotter J, Baldaia C, Ferreira M, Macedo G, Pedroto I. Diagnosis and treatment of iron-deficiency anemia in gastrointestinal bleeding: a systematic review. World J Gastroenterol. 2020;26(45):7242-57.
Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49(12):2719-28.
Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110(2 Pt 1):267-78.
Naqash A, Ara R, Bader GN. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials. BMC Women’s Health. 2018;18(1):6.
Sharma N, Thiek JL, Natung T, Ahanthem SS. Comparative study of efficacy and safety of ferric carboxymaltose versus iron sucrose in post-partum anaemia. J Obstet Gynaecol India. 2017;67(4):253-7.
Rathod S, Samal SK, Mahapatra PC, Samal S. Ferric carboxymaltose: A revolution in the treatment of postpartum anemia in Indian women. Int J Appl Basic Med Res. 2015;5(1):25-30.
Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med. 2012;40(5):469-74.
Kaur R, Kant S, Haldar P, Ahamed F, Singh A, Dwarakanathan V, et al. Single dose of intravenous ferric carboxymaltose prevents anemia for 6 months among moderately or severely anemic postpartum women: a case study from India. Curr Develop Nutr. 2021;5(7):nzab078.
Kant S, Kaur R, Ahamed F, Singh A, Malhotra S, Kumar R. Effectiveness of intravenous ferric carboxymaltose in improving hemoglobin level among postpartum women with moderate-to-severe anemia at a secondary care hospital in Faridabad, Haryana- an interventional study. Indian J Public Health. 2020;64(2):168-72.
Gupte SA, Venkataraman G, Shah AS, Mudholkar AS, Jangam SM. Clinical effects and safety of ferric carboxymaltose in pregnancy: an Indian real-life experience. J Obstet Gynaecol Res. 2021;47(10):3464-70.
Suvarna VR. Real world evidence (RWE)- are we (RWE) ready? Perspect Clin Res. 2018;9(2):61-3.
Charmila A, Natarajan S, Chitra TV, Pawar N, Kinjawadekar S, Firke Y, et al. Efficacy and safety of ferric carboxymaltose in the management of iron deficiency anemia: a multi-center real-world study from India. JBM. 2022;13:303-13.
WHO. WHO: Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011, (WHO/NMH/NHD/MNM/11.1). World Health Organization; 2011. Available from: https://apps.who.int/iris/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf. Accessed on 21 January 2022.
Kalaivani K, Ramachandran P. Time trends in prevalence of anaemia in pregnancy. Indian J Med Res. 2018;147(3):268-77.
Kaur K. Anaemia ‘a silent killer’ among women in India: Present scenario. Eur J Zoolog Res. 2014;3(1):32-6.
Sedlander E, Talegawkar S, Ganjoo R, Ladwa C, DiPietro L, Aluc A, et al. How gender norms affect anemia in select villages in rural Odisha, India: a qualitative study. Nutrition. 2021;86:111159.
Omidvar S, Amiri FN, Bakhtiari A, Begum K. A study on menstruation of Indian adolescent girls in an urban area of South India. J Fam Med Prim Care. 2018;7(4):698-702.
Verma K, Baniya GC. Prevalence, knowledge, and related factor of anemia among school-going adolescent girls in a remote area of western Rajasthan. J Fam Med Prim Care. 2022;11(4):1474-81.
Ghosh P, Dasgupta A, Paul B, Roy S, Biswas A, Yadav A. A cross-sectional study on prevalence and determinants of anemia among women of reproductive age in a rural community of West Bengal. J Fam Med Prim Care. 2020;9(11):5547-53.
Mahey R, Kriplani A, Mogili KD, Bhatla N, Kachhawa G, Saxena R. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int J Gynaecol Obstet. 2016;133(1):43-8.
Mishra V, Verneker R, Gandhi K, Choudhary S, Lamba S. Iron deficiency anemia with menorrhagia: ferric carboxymaltose a safer alternative to blood transfusion. J Midlife Health. 2018;9(2):92-6.
Joshi S. Ferric carboxy maltose a safe and effective alternative in correcting iron deficiency anemia prior to major elective gynecological surgeries. http://www.ejbps.com. 2016. Available from: https://www.academia.edu/44443150/FERRIC_CARBOXY_MALTOSE_A_SAFE_AND_EFFECTIVE_ALTERNATIVE_IN_CORRECTING_IRON_DEFICIENCY_ANEMIA_PRIOR_TO_MAJOR_ELECTIVE_GYNECOLOGICAL_SURGERIES. Accessed on 30 July 2022.
Wani S, Noushad M, Ashiq S. REGAIN STUDY: retrospective study to assess the effectiveness, tolerability, and safety of ferric carboxymaltose in the management of iron deficiency anemia in pregnant women. Anemia. 2019;2019:4640635.
Ikuta K, Hanashi H, Hirai K, Ota Y, Matsuyama Y, Shimura A, et al. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study. Int J Hematol. 2019;109(1):41-9.
Lee S, Ryu KJ, Lee ES, Lee KH, Lee JJ, Kim T. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study. J Obstet Gynaecol Res. 2019;45(4):858-64.